ArticleThe New England journal of medicine2024
Trial Update of Pitavastatin to Prevent Cardiovascular Events in HIV Infection.
Registry-linked trialOpen access · greenAbstract readLetter
In one paragraph
Article in The New England journal of medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT02344290. Cited by 35 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 1 pooled it
24.2field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE
PMID 35235653PMID 32645161PMID 30928825PMID 38533953PMID 36525544PMID 36805331PMID 36825498PMID 36966617PMID 36998633PMID 37439633PMID 37486775PMID 37503623other papers from this trial
Open the trial in the graphWho cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Statin Therapy as Primary Prevention for Persons With HIV: A Synopsis of Recommendations From the U.S. Department of Health and Human Services Antiretroviral Treatment Guidelines Panel.Annals of internal medicine · 2025Guideline
- Incidence, risk factors, and cardiovascular impact of hypertension in people with HIV: a secondary analysis of the REPRIEVE trial.The lancet. HIV · 2026Trial
- Pitavastatin effects on lipids in relation to major adverse cardiovascular events: a REPRIEVE secondary analysis.The lancet. HIV · 2026 · on this mapTrial
- Health-related quality of life among people with HIV at low-to-moderate risk for atherosclerotic cardiovascular disease in the REPRIEVE Trial.AIDS (London, England) · 2026Trial
- Heart Failure Risk and Events in People With HIV: The Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE).Circulation. Heart failure · 2026Trial
- Statin Effects on Pericoronary Adipose Tissue Density in People With HIV: Insights From the REPRIEVE Trial.JACC. Cardiovascular imaging · 2026Trial
- Win Ratio Aligns With and Enhances Interpretation of REPRIEVE's Primary Findings.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Trial
- Clonal Hematopoiesis and Major Adverse Cardiac Events in People With HIV: Insights From the REPRIEVE Trial.Arteriosclerosis, thrombosis, and vascular biology · 2026Trial
- No evidence of pitavastatin effect on muscle area or density among people with HIV.AIDS (London, England) · 2025 · on this mapTrial
- No evidence of a detrimental effect of pitavastatin on neurocognitive function among people with HIV.AIDS (London, England) · 2025Trial
- Effects of antiretrovirals on major adverse cardiovascular events in the REPRIEVE trial: a longitudinal cohort analysis.The lancet. HIV · 2025Trial
- Intensive Lowering of LDL Cholesterol Levels With Evolocumab in Autoimmune or Inflammatory Diseases: An Analysis of the FOURIER Trial.Circulation · 2025Trial
- Statin effects on the incidence of major non-cardiovascular disease events among a global cohort of people with HIV: a randomised controlled trial.The lancet. HIV · 2025Trial
- Pitavastatin Is Well-Tolerated With no Detrimental Effects on Physical Function.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025 · on this mapTrial
- Performance of the pooled cohort equations and D:A:D risk scores among individuals with HIV in a global cardiovascular disease prevention trial: a cohort study leveraging data from REPRIEVE.The lancet. HIV · 2025Trial
- Diabetes Risk Factors in People With HIV Receiving Pitavastatin Versus Placebo for Cardiovascular Disease Prevention : A Randomized Trial.Annals of internal medicine · 2024Trial
- Beyond Lipid Lowering: A Narrative Review and Expert Perspective on Precision Cardiovascular Prevention in People with HIV After REPRIEVE.Biomolecules · 2026Review
- Beyond Statins: Role of Inflammation and Risk of Cardiovascular Events in HIV.JACC. Advances · 2026Article
- Multidisciplinary Care for Older People With HIV: Optimizing Medication and Enhancing Quality of Life.Open forum infectious diseases · 2026Article
- The Gut-Immune Axis in Treated HIV Infection: From Mucosal Damage to Chronic Inflammation and Therapeutic Opportunities-A Clinician-Oriented Narrative Review.Microorganisms · 2026Review
Corrections and comments
- Update of
Authors and funding
3 authors at 3 institutions in 1 country.
Steven K GrinspoonMassachusetts General Hospital, Boston, MA sgrinspoon@mgh.harvard.edu.
Heather J RibaudoHarvard T.H. Chan School of Public Health, Boston, MA.
Pamela S DouglasDuke Clinical Research Institute, Durham, NC.
Clinical Research Institute · USHarvard University · USMassachusetts General Hospital · US
Funding
Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/UM1AI068636 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, RAJESH T GANDHI · 2011 to 2026
$1073.1MStatistical and Data Management Center (SDMC), AIDS Clinical Trials Group (ACTG)UM1AI068634 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Marlene Ann Cooper, Michael David Hughes · 2011 to 2026
$246.6MValidation, CLIA and Qualification (VQC): Enhancing the RS ratio as a tool for AIDS Clinical Trial Group (ACTG) tuberculosis trialsUM1AI106701 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Grace M Aldrovandi · 2014 to 2026
$116.8MDisparities in COVID Disease Severity and Outcomes in New York CityUL1TR002384 · NCATS · WEILL MEDICAL COLL OF CORNELL UNIV · PI JULIANNE L IMPERATO-MCGINLEY · 2017 to 2026
$86.2MVirology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9MREPRIEVE COVID-19 Administrative SupplementU01HL123336 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI DOUGLAS, PAMELA SUSAN, GRINSPOON, STEVEN K. · 2014 to 2021
$52.4MSoweto Clinical Trials UnitUM1AI069453 · NIAID · WITS HEALTH CONSORTIUM (PTY), LTD · PI Glenda E Gray, Lerato Mohapi · 2012 to 2026
$40.9MROLE OF DIETARY CONSTITUENTS ON GENE EXPRESSION IN INTESTINAL EPITHELIUMP30DK040561 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI Elizabeth Austen Lawson, Takara Leah Stanley · 1994 to 2026
$31.6M1/2 REPRIEVE Extension for Trial CompletionUG3HL164285 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI DOUGLAS, PAMELA SUSAN, GRINSPOON, STEVEN K. · 2023 to 2025
$14.2MREPRIEVE - DCCU01HL123339 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI LU, MICHAEL TSE-YIN, RIBAUDO, HEATHER JANE · 2014 to 2019
$6.0M2/2 REPRIEVE Extension for Trial CompletionU24HL164284 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI LU, MICHAEL TSE-YIN, RIBAUDO, HEATHER JANE · 2023 to 2025
$2.9MNCATS NIH HHS UL1 TR002384NHLBI NIH HHS U01 HL123336NHLBI NIH HHS U01 HL123339NHLBI NIH HHS U24 HL164284NHLBI NIH HHS UG3 HL164285NIAID NIH HHS P30 AI050410NIAID NIH HHS UM1 AI068634NIAID NIH HHS UM1 AI068636NIAID NIH HHS UM1 AI069453NIAID NIH HHS UM1 AI106701NIDDK NIH HHS P30 DK040561
Abstract
PubMed holds no abstract for this paper.
Indexed as
Cardiovascular DiseasesHIV InfectionsHydroxymethylglutaryl-CoA Reductase InhibitorsHumansQuinolinesRandomized Controlled Trials as TopicHydroxymethylglutaryl-CoA Reductase InhibitorspitavastatinQuinolines
Identifiers
What Socratic holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT02344290ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.